ASCO Marks Official Launch of Veridex, LLC
New Johnson & Johnson company focused on high-tech cancer diagnostics
NEW ORLEANS, June 5 /PRNewswire-FirstCall/ -- Johnson & Johnson has formed a new company, Veridex, LLC, dedicated to earlier detection of cancer, and more precise staging, monitoring and selection of appropriate therapies. The new company's focus on cancer diagnostics was outlined today at the annual American Society of Clinical Oncology meeting. Utilizing state-of-the-art biology, Veridex is developing high-value, in vitro diagnostic oncology products that will significantly improve patient management and outcomes by providing real-time, predictive medical information to physicians. The company is initially developing two complementary product platforms: CellSearch(TM) assays that identify, enumerate and characterize circulating tumor cells directly from whole blood; and GeneSearch(TM) assays, which employ molecular technology to diagnose, stage and more accurately characterize tumors. Veridex announced the commercial launch of CellSearch(TM) at ASCO, setting a standard for a new class of diagnostic tools. With the growing trend toward more personalized cancer care, these assays will play a key role in supplying critical information to aid oncologists in providing more individualized treatment. According to Mark Myslinski, general manager of Veridex, "Veridex has the opportunity to make a real contribution to patients suffering from cancer by improving their diagnosis through a combination of cellular and gene-based testing. This will offer predictive insight into the nature of an individual's particular cancer, enabling oncologists to prescribe treatment with more fundamental and valuable knowledge of the potential outcome." Cellular Diagnostics: CELLSEARCH(TM) In 2000, Veridex began a collaboration with Immunicon Corporation, a young company developing technologies designed to find rare cells circulating in the blood. This technology, combined with assays from Veridex, makes up the CellSearch(TM) System, the first automated platform for detecting and enumerating circulating tumor cells (CTCs) in peripheral blood. The CellSearch(TM) System has recently been cleared by the FDA for prediction of progression-free and overall survival in patients with metastatic breast cancer and will be available for clinical use by fall 2004. In 2003, Massimo Cristofanilli, M.D., at The University of Texas M. D. Anderson Cancer Center, reported that a clinical trial using CellSearch(TM) technology showed that at disease recurrence, metastatic breast cancer patients with no CTCs had a median survival of more than 24 months, while patients with more than 50 cells had a median survival of only 3.8 months. "CTCs have long been known in theory to exist in peripheral blood," said Robert T. McCormack, Ph.D., general manager, cellular diagnostics, Veridex. "But the technology has never before been available to grasp this potential consistently. Now we have the automation and standardization to make a practical application. Using the CellSearch(TM) System, oncologists will now be able to detect and enumerate CTCs in the bloodstream, giving them critical additional information on which to base their decisions about therapy." Molecular Diagnostics: GENESEARCH(TM) On the molecular side, Veridex is currently working with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (PRD) in La Jolla, California, to develop the company's GeneSearch(TM) technology, which will be able to determine such things as the presence and tissue origin of cancer cells, as well as disease staging, and holds promise for prognostic and therapy selection indications. "Cancer is one of many diseases for which there is a tight correlation between staging and outcome," said David Atkins, Ph.D., general manager, molecular diagnostics. "The earlier you detect disease, the greater the chance of patient survival. The later the disease is staged, the worse the outcome is for the patient. Molecular diagnostics could help catch the disease early enough and classify it specifically enough to treat it appropriately with a much better outcome." Several applications for the GeneSearch(TM) technology are now under development, including an intra-operative assay for sentinel lymph node testing during breast cancer surgery. Veridex is also working with PRD to pursue the identification of a profile that specifies which patients with refractory leukemia are more likely to respond to ZARNESTRA(TM) (tipifarnib), under development for the treatment of hematologic malignancies and other cancers. http://www.veridex.com Contact: Jill S. Gabbe/Stephanie Hughes Koenig, gabbegroup (212) 220-4444 email@example.comfirstname.lastname@example.org Mary Richardson, Veridex, LLC (908) 704-3652 Mrichar3@vrx.jnj.com
SOURCE Veridex, LLC
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.